Showing results (291-300 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|November 14, 2021
Vaccine-induced immune thrombotic thrombocytopeniaFrederikus A Klok, Menaka Pai, Menno V Huisman, et al.
The Lancet. Haematology|November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
The Lancet. Haematology|July 30, 2022
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trialAmy E DeZern, Mary Eapen, Juan Wu, et al.
The Lancet. Haematology|July 28, 2022
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issuesNina Worel, Mahmoud Aljurf, Chloe Anthias, et al.
The Lancet. Haematology|April 14, 2018
Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the NetherlandsSonja E van Roeden, Fedor van Houwelingen, Chiel M J Donkers, et al.
The Lancet. Haematology|May 13, 2018
Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trialQiu-Dan Shen, Hua-Yuan Zhu, Li Wang, et al.
The Lancet. Haematology|June 22, 2020
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international expertsAmer M Zeidan, Prajwal C Boddu, Mrinal M Patnaik, et al.
The Lancet. Haematology|March 4, 2023
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trialEmmanuela E Ambrose, Teresa S Latham, Primrose Songoro, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
The Lancet. Haematology|February 5, 2025
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trialFrida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.
Pageof 73